|
|
 |
|
Viewing report
|
|
|
|
Systemic Fungal Infection Therapeutics Market - South Korea
Frost & Sullivan, Oct 2009, Pages: 43
This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in South Korea.
This Frost & Sullivan research service titled Systemic Fungal Infection Therapeutics Market - South Korea provides an analysis of the current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. This study is aimed at supporting manufacturers in decision making in identifying and prioritizing opportunities in South Korea.
Market Overview
Advances in Diagnostic Tests Allow More Targeted Approaches to the Treatment of Systemic Fungal Infections
With fast-paced advancements in technology, the number of patients diagnosed with systemic fungal infections (SFIs) is expected to increase steadily over the next five years. Alongside this development, a high premium on products that are capable of tackling emergent, problematic pathogens will also contribute to changing market dynamics. Estimates reveal that the global prevalence of SFI has risen to 4 for every 1,000 of the global population. The high incidence of SFI over the years is attributed to the widespread use of broad-spectrum antibiotics, which reduce non-pathogenic bacterial populations that compete with fungi, and the growing number of persons with compromised immune systems caused by acquired immunodeficiency syndrome (AIDS), immunosuppressant drugs, and chemotherapy agents. 'Early diagnosis of systemic fungal infections has been shown to be critical to treatment outcome,' notes the analyst of this research service. 'However, in Korea, early detection of SFI remains a challenge; observations reveal that physicians implement these treatments rather than wait for SFI to develop in the patient.' The introduction of polymerase chain reaction offers an opportunity to improve the rate of early detection of SFI cases in the country.
Although key therapeutics have been in the market to treat the most causative pathogen (Candida Albicans), there is still an unmet need to treat more resistant pathogens such as Aspergillus. Despite the advent of more advanced molecular diagnostic technologies, physicians in South Korea continue to use empiric and prophylactic therapies to treat SFI. As more resistant pathogens in systemic fungal infections emerge, treatment is centered on ensuring that the right treatment is administered to the patient. Doctors are under pressure to ensure that they identify the most suitable mode of treatment, based on universal criteria, such as risk factors, clinical, radiological, microbiological or other diagnostic evidence. This places greater emphasis on matching antifungal choice to pathogen susceptibility, increasing the demand for rapid typing of pathogens to ensure informed, targeted drug choices. Consequently, there would be a reduction in the use of prophylaxis in the ‘at-risk’ patient group and the empiric therapy in, for example, patients in this group with a persistent fever or other suggestive symptoms.
Considering the relatively niche nature of SFI, it is vital for key participants to differentiate their products, especially as advances in diagnostic techniques bring about a restriction of prescriptions to specific therapeutic uses. Therapeutics are shifting away from broad and empiric indications, and pharmaceutical manufacturers need to position their products to address more specific indications defined by pathogen species (and sub species) and patient populations, rather than a broad spectrum. This gives room for a higher degree of differentiation, protecting the specific drug from generic erosion in the future. The changing epidemiology of causative pathogens has caused the effectiveness of existing therapeutic options to decline. In such a scenario, pharmaceutical manufacturers need to develop drugs that address specific indications, in terms of pathogen coverage and patient groups, that is solid organ transplant, cancer, neonates, human immunodeficiency virus (HIV)/AIDS, and surgical patients.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Systemic Fungal Infection Therapeutics Market- Taiwan
Systemic Fungal Infection Therapeutics Research – Malaysia
Systemic Fungal Infection Therapeutics Market – India
Systemic Fungal Infection Therapeutics Market - Australia
Systemic Fungal Infection Therapeutics Market Research – Philippines
Systemic Fungal Infection Therapeutics Market – Singapore
Systemic Fungal Infection Therapeutics Market – China
Systemic Fungal Infection Therapeutics Market – Thailand
Systemic Fungal Infection Therapeutics Market - Hong Kong
Anti-Infective Drugs Markets
|
|
|
|
